Abstract:Background: Mismatch repair deficiency (dMMR) due to germline mutations in DNA repair genes including MLH1, MSH2, MSH6 and PMS2, or somatic aberrant silencing of MLH1, is a well-established feature for Lynch syndrome, a major type of hereditary colorectal cancer (CRC). The purpose of this study is to derive prevalence of germline MMR gene mutations in Chinese population with dMMR CRC. Methods: ColonCore panel is designed for simultaneous detection of microsatellite instabiligy (MSI) status of 22 regions and mutations in 38 CRC-related genes. Whole exons of the 38 genes were covered by the panel. The MSI phenotype detection method was a read-count-distribution-based approach. It utilized the coverage ratio of a specific set of repeat lengths as the main characteristic of each microsatellite locus, and categorized a locus as unstable if the coverage ratio was less than a given threshold. The MSI status of a sample was determined by the percentage of unstable loci in the given sample. Results: Among 1394 postsurgical CRC patients whose MMR status were detected by immunohistochemistry (IHC), 99 patients were dMMR, accounting for 7.1%. The concordance rate was 92.3% between MSI and IHC. Next, we investigated the germline mutation spectrum of dMMR patients. About 26.3% patients harbored pathogenic germline MMR gene mutations, with 13%, 6%, 5% and 2% of patients carrying pathogenic MLH1, MSH2, MSH6 and PMS2 mutations, respectively. Specially, about 30% pathogenic MLH1 mutation occured in splice region. Among patients with pathogenic MMR gene mutations, their first cancer was diagnosed ranging from 22 to 69 years old with median age at diagnosis was 50, and only 57% have a family history of ≥ 1 relative with Lynch syndrome related cancers. Furthermore, 3% harbored pathogenic mutations in other genes. Approximately, 17% of patients harbored MMR gene variants of unknown significance (VUS) and 26% harbored other VUS. The remaining 28% of patients had no pathogenic or VUS mutations from this panel. Conclusions: The prevalence rate of germline pathogenic mutations is 26% in dMMR CRC patients, accounting for 1.8% of all resectable CRC patients. Median age at diagnosis of Lynch syndrome related cancers is 50 years old and nearly 40% Lynch syndrome patients have no family history. Legal entity responsible for the study: Ying Yuan. Funding: Burning Rock Biotech. Disclosure: C. Liu: Burning Rock Biotech. All other authors have declared no conflicts of interest.

Case Report: A Colorectal Cancer Patient with Microsatellite Instability-High and MSH2 Germline Mutation Failed to Respond to Anti-Pd-1 Immunotherapy.

Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor

Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors

The Prevalence of Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome

Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Negative response to immunotherapy in dMMR or MSI-H gastric cancer with APC and PTEN mutations: a case report

Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review

Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Efficacy of PD-1 inhibitors for Colorectal Cancer and Polyps in Lynch Syndrome Patients

Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study

Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms

Efficacy and challenges of anti-PD1 in MSI-H mCRC: a case report on concurrent infections and ir-AIHA

A Pan-Cancer Analysis of Microsatellite Instability As a Predictor of Lynch Syndrome in Chinese Population.

Lower degree of microsatellite instability in colorectal carcinomas from MSH6-associated Lynch syndrome patients

Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review

Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced Dmmr/msi-H/tmb-h Lung Cancer Patient with Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (C.1144+1g>a)

Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.